Leqvio (Inclisiran)

Inclisiran is a small interfering RNA that specifically binds to PCSK9 messenger RNA in liver cells, causing its degradation. Reduced PCSK9 protein leads to increased recycling of LDL receptors, which enhances removal of LDL‑cholesterol from the bloodstream, resulting in sustained cholesterol lowering.

The dosing schedule for Leqvio is determined by the prescribing healthcare professional. Typically, the medication is administered by subcutaneous injection at intervals recommended by the prescriber based on the patient’s clinical profile and treatment goals.

Safety data for inclisiran in pregnancy and lactation are limited. The drug should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Leqvio, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling if needed) and required import documentation.

Leqvio (inclisiran) uses RNA interference to reduce PCSK9 production, whereas monoclonal antibodies bind circulating PCSK9 protein. Both lower LDL‑cholesterol, but inclisiran is administered less frequently (typically twice yearly) and may offer a different safety and convenience profile compared with antibody therapies that require more frequent dosing.

Leqvio should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial to maintain stability and potency.

Leqvio is given as a subcutaneous injection, usually performed by a healthcare professional. The injection is administered into the abdomen or thigh, following the dosing schedule prescribed by the treating clinician.

Serious risks include severe allergic reactions such as anaphylaxis or angioedema, persistent injection‑site infections, significant liver enzyme elevations, and rare immune‑mediated conditions like thrombocytopenia. Patients should be monitored for these events and seek immediate medical attention if they occur.

Leqvio is contraindicated in individuals with known hypersensitivity to inclisiran or any of its excipients. Patients with uncontrolled severe liver disease, active infections at the injection site, or those who cannot receive subcutaneous injections should avoid using this medication.